Breaking News Headlines Today | Ground News

See every side of every news story

Pharmaceutical Business Review image

News from Pharmaceutical Business review

Ground News rates Pharmaceutical Business Review’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Pharmaceutical Business Review’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical Business Review

Where is Pharmaceutical Business Review located?Pharmaceutical Business Review's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical Business Review News

Sensorion Announces €60 Million Financing With a €20M ...

Pharma · Montpellier

Sensorion Announces €60 Million Financing With a €20M ...

Sensorion has announced a $71.9m reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline.See the Story

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Medical · United States

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Biogen Inc. announced that the US FDA has granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class, humanized IgG1 monoclonal antibody targeting blood dendritic cell antigen 2. [Biogen, Inc. ] Press Release See the Story

Insilico, Qilu Pharmaceutical Sign Deal for Cardiometabolic Therapies

Insilico, Qilu Pharmaceutical Sign Deal for Cardiometabolic Therapies

Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical to develop treatments for cardiometabolic diseases.See the Story

Breaking News Topics Related to Pharmaceutical Business Review